ORKA Oruka Therapeutics, Inc.

Oruka Therapeutics' (ORKA) lead program of long-acting IL-23 in moderate-to-severe psoriasis maintai

Oruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.

Oruka Therapeutics recently reported positive Week 28 data from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis, showing deepening clinical responses and a safety profile consistent with the IL-23p19 class. An interesting aspect is that placebo patients who later crossed over to ORKA-001 achieved similar response patterns, underscoring the drug’s potential effect even after delayed initiation. Next, we’ll examine how ORKA-001’s high PASI 100 and PASI 90...

Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names.

Oruka Therapeutics Inc. (NASDAQ:ORKA) on Wednesday reported positive week 28 outcomes from its Phase 2a clinical trial evaluating ORKA-001 for moderate-to-severe plaque psoriasis.The clinical-stage biotechnology firm noted that patient responses improved significantly six months after receiving their final dose of the novel antibody.Phase 2a Trial Demonstrates Deepening EfficacyData showed that 63.5% of treated patients achieved complete skin clearance, or PASI 100, at week 16.Clinical improveme

Oruka Therapeutics, Inc. (NASDAQ:ORKA) shares fell 5% on Wednesday morning after the biotechnology company reported Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis.

Oruka's three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipeline milestones scheduled ahead.

PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.